Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval

Executive Summary

Unlike other indications PD-1/L1 inhibitors are shooting for, Stage III non-small cell lung cancer is an untapped market and AstraZeneca will have the space to itself for a while.

You may also be interested in...



AstraZeneca's Imfinzi Cements Market Position In Lung Cancer Segment With UK NICE Okay

But because of the remaining uncertainty in the clinical evidence for this "potentially curative treatment," – Imfinzi for Stage III NSCLC – UK reimbursement will come from the Cancer Drugs Fund until more data accrues from the PACIFIC study, due to report in 2021.

Q3 Pharma Earnings Preview: AbbVie, Lilly, AstraZeneca And Bayer

AbbVie faces analysts just a couple weeks after Humira biosimilars hit the market, and with Gilead launching authorized generics of its hepatitis C combos, the TNF franchise is not the only one under attack at AbbVie. Investors are keen to see AstraZeneca start its turnaround to growth, while Lilly is looking to a strong future based on new diabetes data and Bayer braces for a new push in oncology.

Q3 Pharma Earnings Preview: Novo Nordisk, Shire And Teva

Pricing pressure and difficulties with market access in competitive classes will be common themes as Teva, Novo Nordisk and Shire report third quarter sales and earnings.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID052006

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel